Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 21 Sep 2016 Status changed from recruiting to completed.
- 26 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Aug 2015 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Jun 2015 to 1 Sep 2015.